|
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) |
|
Recursion Pharmaceuticals Inc
RXRX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Recursion Pharmaceuticals Inc 's sales fell
by -58.26 % in IV. Quarter 2024 from the same quarter a year ago.
Ranking at No. 3165
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -2.45 %
Recursion Pharmaceuticals Inc net loss increased from $-93 millions, to $-179 millions in IV. Quarter 2024,
• More on RXRX's Growth
|
|
Recursion Pharmaceuticals Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 7.66 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 26.25.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.07.
• More on RXRX's Valuation
|
|
|
|
|
Recursion Pharmaceuticals Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 7.66 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 26.25.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.07.
Recursion Pharmaceuticals Inc Price to Book Ratio is at 1.49 lower than Industry Avg. of 17923.75. and higher than S&P 500 Avg. of 0.01
• More on RXRX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com